EVER Valinject GmbH – Trademark Portfolio

Entity Type: 99

EVER Valinject GmbH holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CYTOWRAP.

Oberburgau 3

A-4866 Unterach am Attersee

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

EVER Valinject GmbH's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

16
Paper Goods (1 filing)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

Frequently Asked Questions

How many trademarks does EVER Valinject GmbH have?

EVER Valinject GmbH has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered.

What trademark classes does EVER Valinject GmbH file in?

EVER Valinject GmbH files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 16 (Paper Goods). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are EVER Valinject GmbH's most well-known trademarks?

EVER Valinject GmbH's registered trademark portfolio includes well-known marks such as CYTOWRAP. These are among 1 currently registered trademark in the portfolio.

What is EVER Valinject GmbH's trademark registration success rate?

EVER Valinject GmbH has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.